The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 45 results
Sort by date: Descending
Encores: Not included
Schizophrenia
USPC 2024 POSTER
Acute and Maintenance Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients With Acute Schizophrenia: A Post Hoc Analysis
AUTHOR(S)

Roger S. McIntyre,1 Desiree M. Matthews,2 Marni E. Harris,3 Christina Arevalo,3 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
USPC 2024 POSTER
Study Retention Rates in the OLZ/SAM Phase 3 Clinical Program
AUTHOR(S)

René S. Kahn,1 Christina Arevalo,2 Marni E. Harris,2 David McDonnell3

View poster
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
AMCP Nexus 2024 POSTER
Clinical, Economic, and Humanistic Burden Associated With Narcolepsy: Results From a Systematic Literature Review
AUTHOR(S)

Michael J. Doane,1 Miranda Lauher-Charest,2 Gia Huynh,2 Kristen McCausland2

View poster
Sleep-wake disorders
Bipolar Disorder
AACAP 2024 POSTER
Olanzapine and Samidorphan in Pediatric Patients With Bipolar I Disorder: Pharmacokinetic Results From a Phase 1, Multidose, Open-Label Study
AUTHOR(S)

Melissa DelBello,1 Liming Zhang,2 Ishani Landry,2 David McDonnell,3 Lara Finlayson2

View poster
Bipolar Disorder
Sleep-wake disorders
Sleep Europe 2024 POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Idiopathic Hypersomnia: An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Brendon Yee,1 Ron Grunstein,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2
 

View poster
Sleep-wake disorders
Sleep-wake disorders
Sleep Europe 2024 POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 2 An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

View poster
Sleep-wake disorders